Associations - EGFR exon 19 deletion

EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Front Oncol - 2 weeks
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	erlotinib + ramucirumab Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	gefitinib Sensitive: B - Late Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	icotinib Sensitive: B - Late Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	gefitinib + rivoceranib Sensitive: B - Late Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: B - Late Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	afatinib Sensitive: B - Late Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	gefitinib + ramucirumab Sensitive: B - Late Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	EGFR inhibitor Sensitive: B - Late Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	almonertinib Sensitive: B - Late Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	osimertinib Resistant: C1 - Off-label
EGFR exon 19 deletion EGFR exon 19 deletion	Small Cell Lung Cancer Small Cell Lung Cancer	gefitinib Sensitive: C1 - Off-label
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Cancer Lung Cancer	gefitinib Sensitive: C1 - Off-label
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	gefitinib + osimertinib Sensitive: C2 – Inclusion Criteria
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	anlotinib + icotinib Sensitive: C2 – Inclusion Criteria
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	amivantamab-vmjw Sensitive: C2 – Inclusion Criteria
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGF816 Sensitive: C2 – Inclusion Criteria
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	bevacizumab + erlotinib Sensitive: C2 – Inclusion Criteria
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	amivantamab-vmjw + lazertinib Sensitive: C2 – Inclusion Criteria
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	erlotinib + anlotinib Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR inhibitor Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	rivoceranib + camrelizumab Resistant: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	PD1 inhibitor Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	afatinib + DFP-14323 Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	gefitinib + durvalumab Resistant: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	olaparib + gefitinib Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	X-396 Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	brigatinib Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	alectinib Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	lorlatinib Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	gefitinib + fruquintinib Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	anlotinib + APL-502 Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	gefitinib + anlotinib Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Thymic Carcinoma Thymic Carcinoma	icotinib Sensitive: C4 – Case Studies
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	bevacizumab + atezolizumab Sensitive: C4 – Case Studies
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	erlotinib + ado-trastuzumab emtansine Sensitive: D – Preclinical
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	lenalidomide Sensitive: D – Preclinical
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	CH7233163 Sensitive: D – Preclinical
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Cancer Lung Cancer	BMS-722782 Sensitive: D – Preclinical